Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Windlas Biotech has filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for an initial public offer (IPO) that includes a fresh issue of Rs 165 crore. Besides the fresh issue, there will be an offer for sale of shares. The company will also consider a pre-IPO (Initial Public Offer) placement of up to Rs 50 crore.
The proceeds from the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant - IV and addition of injectables dosage capability at the facility at Dehradun Plant-II. It will also be used for funding incremental working capital requirements, repayment/ prepayment of certain of borrowings and general corporate purposes. Book Running Lead Managers to the issue are SBI Capital Markets, DAM Capital ad IIFL Securities.
Windlas Biotech is into domestic pharmaceutical formulations contract development and manufacturing business.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1687.55 |
Dr. Reddys Lab | 1109.15 |
Cipla | 1463.15 |
Lupin | 1969.05 |
Zydus Lifesciences | 868.25 |
View more.. |